Assembly biosciences presents new data highlighting clinical progress of core inhibitor programs at easl's international liver congress™ 2022

South san francisco, calif., june 22, 2022 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis b virus (hbv) and other viral diseases, today announced data from the company's investigational core inhibitor programs abi-h3733 (3733), abi-4334 (4334) and vebicorvir (vbr), featured in six poster presentations at the  international liver congress™ , the annual meeting of the european association for the study of the liver (easl) taking place virtually and in london on june 22-26, 2022.
ASMB Ratings Summary
ASMB Quant Ranking